15. mart 2012. godine • Hotel M, Beograd, SRBIJA

Pharmaceutical Association of SerbiaPharmacoeconomics Section

Savez farmaceutskih udruženja SrbijeSekcija za farmakoekonomiju

15th March, 2012 • Hotel M, Belgrade, SERBIA

The Second International Conference

THE ROLE OFHEALTH TECHNOLOGYASSESSMENT INREIMBURSEMENT ANDPRIORITY SETTINGSIN HEALTH CARE

Druga međunarodna konferencija

ULOGA PROCENEZDRAVSTVENIH

TEHNOLOGIJA UPROCESU REFUNDACIJE I

USPOSTAVLJANJUPRIORITETA U ZDRAVSTVU

P R O G R A M

The Second International Conference

The role of healTh TeChnologyaSSeSSmenT In reImburSemenT andprIorITy SeTTIngS In healTh Care

15th March, 2012Hotel M, Belgrade, SERBIA

Pharmacoeconomics Section of the Pharmaceutical Association of Serbia (SFUS) is organising the Second International Conference with the topic: “The Role of HTA in the reimbursement process and establishing priorities in healthcare”, which will take place in Belgrade on 15th March 2012.(http://www.farmacija.org).Pharmaceutical Association of Serbia is a voluntary, independent professional association of phar­macists, and other healthcare professionals organized and regulated under the Act of Pharmaceu­tical Association of Serbia. Pharmacoecomics Section was established in May 2006 and it is one of the youngest and fastest growing Sections within Association. Its work is aimed at improving knowledge and skills in pharmacoeconomics, health economics and outcome research in order to allocate limited available resources in health care.The purpose of the Second International Conference is to present HTA development in healthcare systems worldwide and to emphasize the importance of applying HTA in decision making process during reimbursement of medicines and other health care technologies as well as establishing priorities in healthcare field. The aim is also to present characteristics of reimbursement of medi­cines in Central and Eastern European countries and to demonstrate recent development in pric­ing of medicines. An important objective of the Conference is to improve the skills and expertise especially in the area of pharmacoeconomics modelling in developing Markov model. Conference program will be proactive and it will represent unique event in Serbia and region. Participants of the Conference will have opportunity to meet experts from HTA and pharmaco­economics field and exchange their opinions.

We look forward to welcoming you in person at the Second International Conference, organized by

PHARMACOECONOMICS SECTION OF PHARMACEUTICAL ASSOCIATION OF SERBIA

druga međunarodna konferencija

uloga proCene ZdraVSTVenIh TehnologIJa u proCeSu refundaCIJe I uSpoSTaVlJanJu prIorITeTa u ZdraVSTVu

15. mart 2012. godineHotel M, Beograd, SRBIJA

Sekcija za farmakoekonomiju Saveza farmaceutskih udruženja Srbije (SFUS) organizuje Drugu me­đunarodnu konferenciju sa temom: „Uloga procene zdravstvenih tehnologija u procesu refundaci­je i uspostavljanju prioriteta u zdravstvu“ koja će biti održana 15. marta 2012. godine, u Beogradu.(http://www.farmacija.org/).Po svom sadržaju konferencija će predstavljati jedinstven stručni skup ne samo u Srbiji nego i u regionu i verujemo da će biti jako značajna za razvoj farmakoekonomije na našim prostoriima.Cilj konferencije je da se predstavi razvoj procene zdravstve nih tehnologija (Health Tehnology Assessment – HTA) u zdravstvenim sistemima širom sveta i ukaže na značaj primene HTA u procesu donošenja odluka prilikom refundacije lekova i drugih zdravstvenih tehnologija i us­postavljanju prioriteta u zdravstvu, da se predstave osobenosti refundacije lekova naročito u zemljama Centralno istočne Evrope kao i da se prikažu novine u politici formiranja cena lekova. Važan cilj konferencije je unapređenje veština i znanja naročito u oblasti farmakoekonomskog modelovanja.

Velika nam je čast da Vas pozovemo na Drugu međunarodnu konferenciju

SEKCIJE ZA FARMAKOEKONOMIJU SAVEZA FARMACEUTSKIH UDRUŽENJA SRBIJE!

Honorary Board

Prof. dr Ivanka Miletic

Prof. dr Guenka Petrova

Prof. dr Darko Ivanovic

Prof. dr Nada Kovacevic

Prof. dr Ljiljana Tasic

Prof.dr Ana Sabo

Scientific Board

Prof. dr David Banta

Krzysztof Landa

Prof. dr Slobodan Jankovic

Tanja Novakovic

Danka Stefanovic

Organizing Board

Dubravka Urosev

Dragana Rajkovic

Ivana Zaric

Dragana Lakic

4 BOARDS

Počasni odbor

Prof. dr Ivanka Miletić

Prof. dr Guenka Petrova

Prof. dr Darko Ivanović

Prof. dr Nada Kovačević

Prof. dr Ljiljana Tasić

Prof.dr Ana Sabo

Naučni odbor

Prof. dr David Banta

Krzysztof Landa

Prof. dr Slobodan Janković

Tanja Novaković

Danka Stefanović

Organizacioni odbor

Dubravka Urošev

Dragana Rajković

Ivana Zarić

Dragana Lakić

ODBORI 5

08:00-09:00 Registration

09:00-09:15 Opening ceremonyProf. dr Ivanka Miletić, President of Pharmaceutical Association of SerbiaMSc.Pharm Tanja Novakovic, President of Pharmacoeconomics Section, Galenika a.d., Serbia

PANEL 1 - Health Technology Assessment and Decision MakingModerators: Tanja Novakovic; Danka Stefanovic, ADOC d.o.o, Serbia

09:15-10:00 A global perspective on health technology assessment Prof. dr David Banta, University of Maastricht, The Netherlands

10:00-10:30 Decision levels and payer personalities in CEE - the use of HTA information David Danko, Research leader, Corvinus University of Budapest, Institute of Management, Hungary

10:30-10:45 Questions and discussion

10:45-11:15 Coffee networking break

WORKSHOP ONE

11:15-12:55 Markov Model Development Prof dr. Maarten Postma, Professor in Pharmacoeconomics at University of Groningen, the Netherlands Petros Pechlivanoglou, University of Groningen, the Netherlands

12:55-14:00 Lunch break

PANEL 2 - The Role of Health Technology Assessment in Reimbursement ProcessModerators: Tanja Novakovic; Danka Stefanovic, ADOC d.o.o, Serbia

14:00-14:40 Role of HTA in effective management of basic benefit package - introduction of supplementary and complementary health insurance in a country of scarce resources for health care Krzysztof Landa, M.D., CEO of HTA Audit, Poland

14:40-15:15 Polish system in transition – comparison with European countries Magdalena Wladysiuk M.D., HTA Consulting, Poland

15:15-15:30 Questions and discussion

15:30-16:00 Coffee networking break

WORKSHOP TWO

16:00-17:40 Pricing and Reimbursement processes across Europe and their evolution Brian Godman, Institute for Pharmacological Research ‘Mario Negri’, Milan, Italy Prescribing Research Group, University of Liverpool Management School, Liverpool, UK Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden

17:40-17:55 Final test, Evaluation and Closing of the Conference

6 FINAL PROGRAM

08:00-09:00 Registracija učesnika

09:00-09:15 Otvaranje konferencijeProf. dr Ivanka Miletić, predsednica Saveza farmaceutskih udruženja SrbijeMr sci. ph Tanja Novaković, predsednica Sekcije za farmakoekonomiju, Galenika a.d.

PANEL I - PROCENA ZDRAVSTVENIH TEHNOLOGIJA I DONOŠENJE ODLUKAModeratori: Tanja Novaković; Danka Stefanović, ADOC d.o.o, Srbija

09:15-10:00 Globalni pogled na procenu zdravstvenih tehnologijaProf. David Banta, Univerzitet u Mastriktu, Holandija

10:00-10:30 Nivoi odlučivanja i osobenosti refundacije lekova u zemljama centralno istočne Evrope - korišćenje HTA informacija David Danko, Corvinus Univerzitet u Budimpešti, Institut za menadžment, Mađarska

10:30-10:45 Pitanja i diskusija

10:45-11:15 Kafe pauza

KRATAK KURS 1

11:15-12:55 Izrada Markovljevog modelaProf. Maarten Postma, profesor farmakoekonomije, Odsek za farmakoepidemiologiju i farmakoekonomiju, Univerzitet u Groningenu, HolandijaPetros Pechlivanoglou, Univerzitet u Groningenu, Holandija

12:55-14:00 Pauza za ručak

PANEL II - ULOGA HTA U PROCES REFUNDACIJEModeratori: Tanja Novaković; Danka Stefanović, ADOC d.o.o, Srbija

14:00-14:40 Uloga HTA u efikasnom upravljanjanju paketa osnovnih zdravstvenih usluga - uvođenje dopunskog i dodatnog zdravstvenog osiguranja u zemlji ograničenih resursa za zdravstvenu zaštitu Krzystof Landa, HTA Audit, Poljska

14:40-15:15 Zdravstevni sistem Poljske u tranziciji - poređenje sa zemljama Evrope Magdalena Wladysiuk, HTA Consulting, Poljska

15:15-15:30 Pitanja i diskusija

15:30-16:00 Kafe pauza

KRATAK KURS 2

16:00-17:40 Formiranje cena lekova i procesi refundacije širom Evrope i njihov razvoj Brian Godman, Institut za farmakološko istraživanje ‘Mario Negri’, Italija; Univerzitet u Liverpulu, UK; Odsek za kliničku farmakologiju, Karolinska Univerzitetska bolnica, Švedska

17:40-17:55 Evaluacije konferencije i zatvaranje konferencije

FINALNI PROGRAM 7

David Banta

David Banta was professor of Health Technology Assessment at Maastricht University, Maas­tricht, the Netherlands, from 1988­2003 and (Emeritus from 2003). David Banta joined the US Congressional Office of Technology Assessment (OTA) in 1975, just after the Congressional Board established a health program. He worked there for two years, mainly on the subject of efficacy and safety, and then came back as head of the health program in 1978. In 1983 he left OTA and went to WHO in Washington, but then he was invited to the Netherlands to head a study on future health technology. That invitation came because HTA was getting quite a lot of attention because of OTA’s early work, and he was having a lot of visitors to Washington from around the world. He began to work in Hague, but he also began to get more and more invitations to go to different countries and advise them what to do about health technology. He spent quite a bit of time in China, Malaysia, Brazil, Serbia, and Poland. He spent periods of more than a week in other countries, including Japan, Korea, India, Australia, Lebanon, Israel, Mexico, Chile and Argentina, most of the European countries (almost all of Western European countries and in many eastern European countries). Professor Banta has long experience in health technology assessment in all its aspects. He contributed with extensive experience in consulting in different countries on HTA in relation to the health system and health policies of that country. Professor Banta has special interest and expertise in health insurance coverage decisions in relation to HTA.

Dávid Dankó

Dávid Dankó is research leader at the Institute of Management of the Corvinus University of Budapest, where he is lecturer on pharmaceutical and medical device reimbursement, health care management and strategic management. He is also managing director of Ideas & Solu­tions, a strategic advisory firm which works together with leading pharmaceutical and medical device manufacturers on making new medicines acccesible, as well as local portfolio strategies and patient adherence management.

Having studied in Sweden and Germany, he received his MSc degree in Economics at Cor­vinus in 2003, and went on to pursue PhD research in the field of long­term resource manage­ment in the innovative pharmaceutical industry. In Spring 2012, he will be defending his PhD thesis, and publishing a comprehensive textbook on pharmaceutical reimbursement policy.

Between 2003 and 2008, he worked as a consultant specialized in health care and life sci­ences, working with local and multinational companies as well as the Hungarian government. His consulting and expert assignments were mainly focused on health care reform, strategy formulation and implementation, and business planning.

Between 2008 and 2010, he worked on the payer side, as deputy head for strategy, analysis and integration of the Department of Reimbursement at the Hungarian National Health Insur­ance Fund Administration, where he was primarily responsible for pharmaceutical and medical device reimbursement strategy, concept development, international co­operations, and the co­ordination of IT development as well as research and analysis activities.

8 BIOGRAPHY

David Banta

Profesor David Banta je od 1988. do 2003. godine bio profesor predmeta procene zdravstevnih tehnologija (Health Techology Assessment­ HTA) Mastrikt Univerziteta u Holandiji. Od 2003. godine je profesor Emeritus. Profesionalni razvoj profesora Bante vezan je za razvoj HTA. Banta je svoju kari­jeru počeo 1975. godine u Američkom Kongresu u kancelariji za procenu zdravstvenih tehnologija (US Congressional Office of Technology Assessment – OTA) kad je Kongres osnovao zdravstveni program gde je radio dve godine, uglavnom na poslovima efikasnosti i bezbednosti zdravstvenih tehnologija. 1978. godine, postaje rukovodilac zdravstvenog programa u OTA da bi 1983. godine prešao u Vašin­gton u Svetsku zdravstvenu organizaciju (SZO). Međutim iste godine je pozvan da u Holandiji bude vođa projekta o budućnosti zdravstvenih tehnologija. Poziv u Holandiju je usledio, jer je HTA zaoku­pljala puno pažnje zbog ranog rada američke kancelarije za procenu zdravstvenih tehnologija. On je svoj rad na razvoju HTA počeo u Hagu, ali je ubrzo dobijao pozive iz različitih zemalja koje je savetovao u oblasti HTA. Tako je on dosta vremena proveo u Kini, Maleziji, Brazilu, Srbiji i Poljskoj. Kraće periode je proveo i u drugim zemaljama uključujući Japan, Koreju, Indiju, Australiju, Liban, Izrael, Meksiko, Čile i Argentinu. Takođe je boravio u većini evropskih zemalja, u svim zemljama Zapadne Evrope i u mnogim zemljama istočne Evrope. Profesor Banta je bio predavač na velikom broju međunarodnih konferencija, tako da je upoznao situaciju zemalja u Africi i drugim zemljama u Aziji, Bliskom Istoku i Južnoj Americii i autor je brojnih naučnih radova i knjiga vezanih za HTA. Profesor David Banta ima dugogodišnje iskustvo procene zdravstvenih tehnologija u svim njenim aspektima, bogato iskustvo u savetovanju u različitim zemljama HTA u vezi sa zdravstvenim sistemima i zdravstvenom politikom te zemlje. Poseban interes i ekspertiza za odluke zdravstvenog osiguranja u odnosu na HTA.

David Danko

David Danko je vodeći istraživač Instituta za menadžment Univerziteta Corvinus u Budim­pešti, Mađarskoj, gde predaje predmet refundacija lekova i medicinskih sredstava, menadžment zdravstvene zaštite i strateški menadžment. Takođe je generalni direktor konsultanske kompa­nije Ideas & Solutions, specijalizovane za oblast zdravstva gde sarađuje sa vodećim proizvođa­čima lekova i medicinskih sredstava na kreiranju pristupa novim lekovima, lokalnih portfolio strategija i pacijentovog pridržavanja terapije.

Nakon završenih studija u Švedskoj i Nemačkoj, 2003. godine magistrirao ekonomiju na Corvinus Univerzitetu, a na proleće 2012. godine će braniti doktorsku tezu i objaviti udžbenik o politici refundacije lekova. U periodu od 2003­2008. godine radio je kao konsultant speci­jalizovan u oblasti zdravstvene zaštite sa lokalnim i multinacionalnim kompanijama kao i za Vladu Mađarske. Od 2008­2010. radio je kao zamenik šefa Odeljenja za refundaciju mađarskog nacionalnog zavoda za zdravstveno osiguranje gde je bio prvenstveno odgovoran za strategije refundacije lekova i medicinskih sredstava, koncept razvoja međunarodne saradnje i koordina­cije IT razvoja, kao i za istraživačke i analitičke aktivnosti. David Danko je predavač na Fakulte­tu za klinička istraživanja u Beču, Univerzitetu u Lionu (EMAUD), Semmelweis Univerzitetu u Budimpešti, Eötvös Lorand Univerzitetu, redovan je predavač na međunarodnim radionicama i konferencijama iz oblasti refundacije lekova i medicinskih sredstava.

BIOGRAFIJE 9

Dávid Dankó is a lecturer at Vienna School of Clinical Research, Université Lyon 1 (EMAUD), Semmelweis University of Budapest, Eötvös Lorand University, and he a regular speaker at inter­national workshops and conferences on pharmaceutical and medical device reimbursement.

Maarten Postma

Prof Maarten J Postma holds the chair in Pharmacoeconomics at the University of Gron­ingen (Netherlands). Also, he holds an honorary chair in Health Economics at the University Medical Center Groningen. He did his MSc in econometrics and his PhD in health economics. Next to being head of the Unit PharmacoEpidemiology & PharmacoEconomics of the Depart­ment of Pharmacy and being in the board of directors of the Department, he specifically leads a team of 15 PhD and post­doc researchers in health­ and pharmacoeconomics, contributing to many international research networks (co­operations with the University of London, Mario Negri in Italy, University of Ghent, the University of Munich, University la Rioja) and scientific communications. He serves (served) on various committees advising the Dutch government on reimbursement of drugs (“Commissie Farmaceutische Hulp”) and vaccines (Health Council). Also, he is advisor to various health­economics consultancy companies worldwide, member of editorial boards of scientific journals, on advisory boards for pharmaceutical companies and consultant for WHO. He has approximately 160 MEDLINE­publications and an H­factor of 20.

Petros Pechlivanoglou

Petros Pechlivanoglou is PhD candidate in the subject of Statistical Analysis of Pharma­ceutical Data, at the unit of Pharmacoepidemiology and Pharmacoeconomics, department of Pharmacy, University Of Groningen, Groningen, the Netherlands. He finished year under­graduate studies at the Department of Economic Sciences, University Of Macedonia, Thes­saloniki, Greece. He is experienced in teaching following subjects: Pharmacoepidemiology, Ad­vanced Pharmacoeconomics, Introduction to Pharmacoeconomics, Introduction to statistical programming in R . He participated on international seminars and workshops, in conjunction with Applied Economics (University Macedonia, Thessaloniki), statistics in medicine (Bergamo, Italy) and multi­stage analysis (University of Groningen, The Netherlands). He is author and coauthor of 11 publications, 11 papers and 7 poster presentations at the European Congress of ISPOR. From 2010 to 2011. he was engaged on the project funded by the Dutch organization for research and development in health, as well as the project funded by MSD (2011­2012).

Krzysztof Landa

The CEO of HTA Audit, a company dealing with quality of HTA reports directed to au­thorities and public institutions in Poland and the President of Watch Health Care Foundation (www. WatchHealthCare.eu). From 2010 till 2011 he was President of the Central & Eastern Eu­ropean Society of Technology Assessment in Health Care (www.CEESTAHC.org). In 2006­2007

10 BIOGRAPHY

Maarten Postma

Profesor Maarten Postma je rukovodilac jedinice za farmakoepidemiologiju i farmakoekono­miju, katedre za farmaciju, Univerziteta u Groningenu (Holandija), kao i počasni član zdravstvene ekonomije medicinskog centra Univerziteta u Groningenu. Magistrirao je ekonometriju, a doktori­rao zdravstvenu ekonomiju. Profesor Postma vodi tim od 15 doktoranata i posle doktorskih istra­živača iz oblasti farmakoekonomije i zdravstvene ekonomije, doprinoseći širenju međunarodne istraživačke mreže (saradnja sa Univerzitetom u Londonu, Mario Negri u Italiji, Univerzitetom u Gentu, Univerzitetom u Minhenu i Univerzitetom u Rioji). Član je raznih odbora koji savetuju vladu Holandije o naknadi lekova i vakcina, član uredjivačkog odbora naučnih časopisa, član savetodavnih odbora farmaceutskih kompanija, savetnik je raznim kompanijama vezano za pitanja zdravstvene ekonomije, kao i konsultatan Svetske zdravstvene organizacije. Ima oko 160 MEDLINE publikacija.

Petros Pechlivanoglou

Petros Pechlivanoglou je na doktorskim studijama iz predmeta statističke analize farmace­utskih podataka katedre za farmakoepidemiologiju i farmakoekonomija, Univerziteta u Gronin­genu, Holandija. Završio je osnovne studije ekonomije na Univerzitetu Makedonija, Solun, Grč­ka i postdiplomske studije iz ekonometrije, Ekonomskog fakulteta, Univerziteta u Groningenu, Holandija. Iskusan je kao predavač u sledećim predmetima: Farmakoepidemiologija, Viši nivo iz farmakoekonomije, Uvod u farmakoekonomiju, Uvod u statističko programiranje. Učestvovao je na međunarnodnim seminarama i radionicama a, u vezi sa primenjenom ekonomijom (Uni­verzitet Makedonija, Solun), statistikom u medicini (Bergamo, Italija) i višestepenim analizama (Univerzitet Groningen, Holandija). Autor je i koautor u 11 publikacija, 11 radova i 7 poster pre­zentacija na ISPOR evropskim kongresima. Od 2010­2011. godine bio je angažovan na projektu koji finansira holandska organizacija za istraživanja i razvoj u zdravstvu, kao i na projektu koji finansira MSD (2011­2012).

Krzysztof Landa

Krzysztof Landa je generalni direktor kompanije HTA Audit, koja se bavi procenom kvalite­ta izveštaja procena zdravstvenih tehnologija namenjenih državnim institucijama u Poljskoj. Takođe je predsednik Watch Health Care Foundation (www.WatchHealthCare.eu). Od 2010 – 2011. godine je bio predsednik Udruženja Central & Eastern European Society of Technology Assessment in Health Care (www.CEESTAHC.org). 2004.godine je izabran za člana borda direk­tora međunarodne orgazanizaije za HTA – HTAi i na dužnosti je bio do 2007. godine. Dr Landa je bio predsednik naučnog odbora Prvog godišnjeg HTAi sastanka u Krakovu, Poljska. Diplomi­rao na Medicinskom fakultetu, a postdiplomske studije iz menadžmenta završio na Institutu za javno zdravlje Jagiellonian Univerziteta u Krakovu. Promocija HTA u CEE regionu rezultirala je međunarodnom saradnjom u edukaciji i HTA. Dr Landa je organizovao brojne nacionalne i međunarodne HTA kurseve i konferencije.

BIOGRAFIJE 11

Dr Landa was the Director of Drug Policy Department in the Central Office of National Health Fund. In 2004 Krzysztof Landa was elected to the Board of Directors of Health Technology As­sessment International (HTAi) and performed his duties till mid 2007. He was the Chairman of the LOC of the first HTAi Annual Meeting 2004, held in Krakow, Poland. Dr. Landa is a graduate of the University School of Medicine and received his management education at the Postgradu­ate School of Public Health of Jagiellonian University in Krakow. Promotion of HTA in the region of CEE resulted in international cooperation in education and HTA. Dr. Landa organized many national and international HTA workshops and conferences.

In years 2006­2008 Dr. Landa provided consultancy for the Serbian Ministry of Health.He was team leader of the World Bank project aimed at introduction of HTA in Serbia,

implementation of EBHC principles to the management of basic benefit package and designing a governmental HTA Agency.

Magdalena Wladysiuk

Magdalena Wladysiuk is Vice president and owner of HTA Consulting. She is a medical doc­tor with MBA in Technology Management. She is one of the author of 100 HTA reports for industry and public health insurance and financial analyses developed since 2001 (some in Polish and in English can be found on www.hta.pl/raports). From 2006 till 2008 she provided consultancy for the Serbian MoH in respect to evidence based BBP, design and feasibility study on different models of HTA Agency in Serbia, quality of practice guidelines, EBHC development and HTA systemic implementation, in­depth training of Serbian HTA analysts and develop­ment of 3 country specific HTA reports.

Currently she is working closely with MOH Poland counterparts and private sector, developed strategic planning, economic analysis, health promotion, standards, cost reduction and clinical/health information systems. Magdalena Wladysiuk is involved in promotion of HTA in the region of CEE which resulted in international cooperation in education and HTA. She is organizing many national and international HTA workshops and conferences and speaker at most of them.

Brian Godman

Brian Godman is researcher at Division of Clinical Pharmacology, Karolinska Institute, Stock­holm, Sweden and also positions with Mario Negri Institute for Pharmacological Research, Milan, Italy and Prescribing Research Group, Liverpool University, United Kingdom. Brian Godman is ac­tively working with health authorities and health insurance companies across Europe, South Amer­ica, UAE (Abu Dhabi) and USA, evaluating the impact of measures to enhance both the quality and efficiency of prescribing of both new and existing products. This includes Serbia. Prior to active research, Brian spent thirteen years in European and Global healthcare consultancy undertaking numerous projects including appraising current and planned reforms to enhance the quality and ef­ficiency of prescribing, their transferability, and implications for all key stakeholders groups. It also included evaluating developments in the pricing and reimbursement of drugs and their influence on product development and market access strategies. He is author of 37 scientific journals.

12 BIOGRAPHY

Od 2006 ­ 2007. godine Krzysztof Landa je bio direktor Odeljenja za lekove u Nacionalnom zdravstvenom fondu Poljske. Od 2006­2008. godine bio je konsultant za Ministarstvo zdravlja Republike Srbije i vođa tima na projektu Svetske banke za uvođenje HTA u Srbiju, implementaciju paketa osnovnih zdravstvenih usluga zasnovanih na dokazima i projektovanje HTA agencije.

Magdalena Wladysiuk

Magdalena Wladysiuk je podpredsednica i vlasnik kompanije HTA Consulting u kojoj je od osnivanja 2001. godine. Jedan je od autora 100 različitih HTA izveštaja za farmaceutsku indu­striju i fondove zdravstvenih osiguranja i finansijskih analiza (neke na poljskom i na engleskom se mogu naći na sledećem web sajtu www.hta.pl/raports). Učestvovala je u razvoju metodo­logije, strukture i inicijalne namene osnovnog paketa zdravstvenih usluga za Poljsku. Član je Udruženja Central & Eastern European Society of Technology Assessment in Health Care. Od 2006­2008. godine radila je kao konsultant za Ministarstvo zdravlja Republike Srbije za imple­mentaciju zdravstvene zaštite zasnovane na dokazima, osnovnog paketa zdravstvenih usluga zasnovanog na dokazima, studiju izvodljivosti za različite modele HTA Agencija, razvoj medi­cine zasnovane na dokazima, sistemsku implementaciju HTA, sveobuhvatni trening iz oblasti HTA analize i izradu 3 HTA vodiča čije su teme izabrane od strane Ministarstva zdravlja. Trenut­no blisko sarađuje sa kolegama iz Ministrastva zdravlja Poljske i privatnog sektora na razvoju strateškog planiranja, ekonomskih analiza, promociju zdravlja, standarda, redukcije troškova i kliničkog / zdravstvenog informacionog sistema. Magdalena Wladysiuk učestvuje aktivno u promociji HTA u CEE regionu što je rezultiralo u međunarodnoj saradnji u oblasti obrazovanja i HTA. Ona je organizovala brojne nacionalne i međunarodne HTA kurseve i konferencije i go­vornik je na većini njih.

Brian Godman

Brian Godman je istraživač pri Odseku za kliničku farmakologiju, Univerzitet Karolinska, Švedska i takođe sa pozicijom na Institutu za farmakološko istraživanje ‘Mario Negri’, Italija i na Univerzitetu u Liverpulu, Velika Britanija. Osnovne studije je završio na King’s College, Lon­don, Velika Britanija iz oblasti farmakologije, a zvanje doktora nauka je ostvario 2011. godine na Open University, u Velikoj Britaniji.

Brian aktivno sarađuje sa zdravstvenim autoritetima i zdravstvenim osiguravajućim društvi­ma u Evropi, Južnoj Americi, UAE (Abu Dabi) i SAD, procenjujući uticaj mera da bi se poboljšao kvalitet i efikasnost propisivanja novih i postojećih proizvoda, uključuju i Srbiju. Pre aktivnog istraživačkog rada, Brian je proveo trinaest godina u evropskim i svetskim konsultantskim agen­cijama preduzimajući brojne projekte, uključujući ocjenjivanje trenutnih i planiranih reforme kako bi se poboljšao kvalitet i efikasnost propisivanja, njihovu prenosivost i implikacije za sve ključne interesne grupe. Takođe je radio na proceni kretanja cena i refundacije lekova i njihovog uticaja na razvoj proizvoda i strategije pristupa tržištima. Autor je oko 37 radova objavljenih u celosti u međunarodnim naučnim časopisima.

BIOGRAFIJE 13

14 NOTES

NOTE Program of the Conference is accredited by the decision of the Health Council of ••Serbia (accreditation number B­8/12) as a First category International course, for pharmacists and physicians with 7 points for the listeners and 13 points for lectures. English is official language of the Congerence. ••

BELEŠKE 15

OBAVEŠTENJE Program Konferencije akreditovan je Odlukom Zdravstvenog saveta Srbije (akredi ta­••cioni broj B­8/12) kao Međunarodni kurs I kategorije, za ciljnu grupu farmaceute i lekare sa 7 bodova za slušaoce i 13 bodova za predavače. Zvaničan jezik konferencije je engleski. ••

Golden Sponsor / Zlatni sponzor

Other Sponsors / Ostali sponzori

Media Partners / Medija partneri